Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
ARVN Stock Chart & Stats
$13.39
$0.30(1.54%)
At close: 4:00 PM EST
$13.39
$0.30(1.54%)
Day’s Range― - ―
52-Week Range$5.90 - $20.38
Previous CloseN/A
Volume216.17K
Average Volume (3M)663.83K
Market Cap
$859.96M
Enterprise Value$859.49M
Total Cash (Recent Filing)$787.60M
Total Debt (Recent Filing)$9.50M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 02, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding64,224,300
10 Day Avg. Volume796,516
30 Day Avg. Volume663,830
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.45
Price to Sales (P/S)5.23
P/FCF Ratio-5.28
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue2.75
Enterprise Value/Gross Profit2.75
Enterprise Value/Ebitda-9.77
Forecast
1Y Price Target
$16.40Price Target Upside22.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
KRAS G12D CandidateAnalyst highlights ARV-806's preclinical profile showing substantially greater potency than competitors and the ability to degrade both active and inactive KRAS G12D, producing tumor regressions and synergy with immune checkpoint therapies that could differentiate the program commercially.
Parkinson's ProgramAnalyst notes ARV-102 demonstrates central nervous system penetration and strong target engagement with LRRK2 biomarker modulation in Parkinson's patients, supporting its potential as a competitive therapeutic option.
Pipeline FocusAnalyst notes the company is simplifying its strategy to concentrate on early-stage pipeline programs, which could accelerate milestone delivery and improve investor clarity.
Bears Say
Commercial DifferentiationAnalyst cautions that mixed clinical results for vepdeg may weaken the drug's ability to clearly outperform existing therapies, creating uncertainty around future market uptake and pricing power.
Investor Sentiment And VolatilityAnalyst flags that unresolved efficacy questions in the vepdeg submission could drive investor uncertainty and stock volatility around regulatory review milestones.
Regulatory RiskAnalyst warns the NDA filing for vepdeg is supported by mixed data, with progression-free survival not meeting a previously identified differentiation threshold, increasing the risk of regulatory setbacks or label limitations.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $5.90 and its highest was $20.38 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $859.96M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Mar 02, 2026 which is in 24 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Nov 05, 2025. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.697 by $0.217.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.51.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 64,224,300 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.697. Following the earnings report the stock price went up 0.314%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arvinas Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.40 (22.48% Upside)
$16.40 (22.48% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 159.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.84%
12-Months-Change
Fundamentals
Return on Equity
-10.17%
Trailing 12-Months
Asset Growth
-27.66%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
ARVN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed significant progress in Arvinas' clinical pipeline, particularly with ARV-102 and financial stability, but was tempered by a notable revenue decline and ongoing challenges in achieving efficacious exposure levels in some trials.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$16.40
▲(22.48% Upside)
Technical Analysis
AnaptysBio
―
Meiragtx Holdings
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.33% Insiders
19.21% Mutual Funds
0.17% Other Institutional Investors
63.76% Public Companies and
Individual Investors